INCY

Incyte Corporation

Industrials
92.24 -3.35 -3.50% Market Closed
2026-06-02 • USD

Key Metrics

Market Cap 18.43B
EV —
Shares Out 199.78M
Revenue (ttm) 5.36B
Net Income 1.43B
Beta —
P/E 11.96
Forward P/E —
EPS (ttm) $7.08
P/S —
P/B 3.27
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA 19.51%
ROE 29.24%
ROIC —
Gross Margin —
Oper. Margin 30.05%
Profit Margin 26.71%
Debt/Eq 0.00
LT Debt/Eq —
Quick Ratio —
Current Ratio 3.68
Book/sh 28.21
Cash/sh 17.36
Div Yield —
Div TTM —
Payout Ratio —
SMA20 -5.09%
SMA50 -3.86%
SMA200 -3.7%
Volume 1,940,827
Avg Volume 1.60M
Rel Volume —
Perf Week -4.65%
Perf Month -5.37%
Perf Quarter -5.23%
Perf Half Y -10.03%
Perf YTD -6.61%
Perf Year 37.18%
Perf 3Y 47.89%
Perf 5Y 10.69%

Factor Lens

Seasonal Performance

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Incyte is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics. The Company's global headquarters is in Wilmington, Delaware, with additional offices in Morges (Switzerland), Tokyo (Japan), Montreal (Canada), and across Europe. Incyte is focused in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity (IAI). In Hematology, the Company markets JAKAFI (ruxolitinib) for myelofibrosis, polycythemia vera, and graft-versus-host disease; ICLUSIG (ponatinib) for chronic and acute myeloid leukemia; MONJUVI/MINJUVI (tafasitamab) for diffuse large B-cell lymphoma and follicular lymphoma; and NIKTIMVO (axatilimab) for chronic graft-versus-host disease. In Oncology, the Company markets ZYNYZ (retifanlimab) and PEMAZYRE (pemigatinib). In IAI, the Company markets OPZELURA (ruxolitinib cream) for atopic dermatitis and vitiligo. The Company operates through its own specialty sales force and through collaboration agreements with partners including Novartis for ruxolitinib outside the United States and Eli Lilly for certain development programs. The Company has a clinical pipeline with multiple programs in hematology, oncology and immunology, including development-stage candidates in GVHD, myeloproliferative neoplasms, B-cell malignancies, solid tumors, and inflammatory skin diseases.

Name
Incyte Corporation
Industry
Industrials
CEO
William J. Meury · Chief Executive Officer
Employees
3,200 as of 2025-12-31
IPO Date
2019-01-02
Phone
(302) 498-6700
Address
1801 Augustine Cut-Off, Wilmington, DE 19803
Website
https://www.incyte.com

Key Executives

Name Title FY Pay
Jean-Jacques Bienaimé Independent Director —
Julian C. Baker Chair of the Board —
Richard Hoffman Secretary —
Hervé Hoppenot President and Former Chief Executive Officer —
William J. Meury Chief Executive Officer —

Latest News